The Taskforce notes the publication of results of the tocilizumab arm of the RECOVERY trial in medRxiv Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial on February 11.
The Taskforce Disease Modifying Treatment and Chemoprophylaxis Panel will review the data from this important trial and incorporate the results into the body of evidence underpinning our current recommendation for tocilizumab.
Recommendations regarding the use of tocilizumab will be updated as appropriate in future versions of the guidelines.